Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA litargirio warning

This article was originally published in The Rose Sheet

Executive Summary

Consumers should immediately stop all use of litargirio powder, which is commonly found in deodorant, foot fungicide and burn and wound treatment products, agency announces. FDA is working with the Consumer Product Safety Commission to alert public to risks of lead poisoning after ingestion or contact with skin. Powder is a traditional remedy popular in the Dominican Republic that does not have any proven health benefits and is particularly harmful to children, agency points out. Rhode Island Department of Health alerted FDA to product's dangers after several children using litargirio as deodorant were treated for lead poisoning...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS011579

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel